ResearchType 1 DiabetesIs empagliflozin a disease-modifying therapy for adult-onset type 1 diabetes?
Investigators: A/Prof John Wentworth and Prof Peter Colman Summary: A single-arm safety and feasibility study of 6 months of empagliflozin therapy, started within 100 days of T1D diagnosis. Outcomes include adverse events, glycaemic variability and C-peptide response to mixed meal. Inclusion criteria:
Royal Melbourne Hospital, 300 Grattan Street, Parkville 3050 Recruitment duration: Until participant limit reached. Contact details: A/Prof John Wentworth E: [email protected] M: 0422 992 891 Type 2 DiabetesGestational DiabetesThyroid DysfunctionThyroid CancerOsteoporosisThe Efficacy of Denosumab in Preventing Bone Microstructural Decay in Premenopausal Women with Early Breast Cancer Being Treated with Ovarian Suppression and Aromatase Inhibition - A Randomised Controlled Trial
Investigators: Sabhashini Ramchand, Mathis Grossmann, Ego Seeman, Jeffrey Zajac Summary: -In premenopausal women with early ER-positive breast cancer, combined ovarian suppression and aromatase inhibition result in a precipitous decline in oestradiol production. This is likely to lead to bone loss and increased fracture risk in these young women. The aim of this study is to evaluate the efficacy of denosumab, initiated at the start of ovarian suppression, in preventing bone microstructural decay. We will use a novel imaging tool, HRpQCT, to analyse bone microstructure. -Participants are required to have 4 study visits over 12 months with study investigations including DEXA, HR-pQCT, blood tests, questionnaires, and medical reviews. Inclusion criteria:
Study site: Austin Hospital, 145 Studley Road, Heidelberg, Victoria. Recruitment duration: Until end 2018. Contact details: Dr Sabashini Ramchand E: [email protected] M: 0478 168 578 F: 9496 2980 (attention: Dr S Ramchand) Effects of cross-sex hormone therapy on bone microarchitecture in transgender individuals
Investigators: Dr Ingrid Bretherton Summary: We are running a prospective longitudinal as well as a cross sectional study looking at the impact of cross sex hormones on bone health, body composition, and metabolic risk. The prospective study involves 5 study visits over 2 years. The cross sectional study involves a single study visit. Each study visit involves a blood test, a DXA and HR-pQCT scan. These are both low radiation scans (not above background levels of radiation exposure). All study visits are at the Repatriation Hospital. Inclusion criteria:
Repatriation Hospital, Austin Health Recruitment duration: Prospective: until end 2019, Cross sectional: until early 2018 Contact details: Dr Ingrid Bretherton E: [email protected] P: 9496 2486 PituitaryProject Title
Investigators: Summary: Inclusion criteria: Major exclusions: Study site: Recruitment duration: Contact details: |
|